{"id":745423,"date":"2016-01-19T10:00:00","date_gmt":"2016-01-19T10:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\/"},"modified":"2025-11-07T01:26:02","modified_gmt":"2025-11-07T06:26:02","slug":"data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\/","title":{"rendered":"Data for KEYTRUDA\u00ae (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium"},"content":{"rendered":"<p class=\"bwalignc\">       Seven Registration-Enabling Trials Evaluating KEYTRUDA in Patients        with Gastrointestinal Cancers are Planned or Underway     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that new and updated findings investigating the use of<br \/>\n      KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the company\u2019s anti-PD-1 therapy,<br \/>\n      in multiple gastrointestinal cancers will be presented at this year\u2019s<br \/>\n      Gastrointestinal (GI) Cancers Symposium in San Francisco, Jan. 21 \u2013 23.<br \/>\n      Updates on pembrolizumab include data on advanced esophageal carcinoma<br \/>\n      and new preliminary Phase 2 safety data in gastric cancer.\n    <\/p>\n<p>\n      \u201cAdvanced gastrointestinal cancers are difficult to treat and new<br \/>\n      therapies are needed,\u201d said Roger Dansey, M.D., senior vice president<br \/>\n      and therapeutic area head, oncology late-stage development, Merck<br \/>\n      Research Laboratories. \u201cThrough our rapidly advancing clinical program,<br \/>\n      we have seen promising results with KEYTRUDA in several gastrointestinal<br \/>\n      cancers, and are hopeful about the potential of KEYTRUDA for these<br \/>\n      patients.\u201d\n    <\/p>\n<p>\n      The KEYTRUDA clinical trials program currently includes more than 30<br \/>\n      tumor types in more than 200 clinical trials, including more than 80<br \/>\n      trials that combine KEYTRUDA with other cancer treatments. More than 20<br \/>\n      of these trials are evaluating KEYTRUDA in gastrointestinal cancers,<br \/>\n      including seven registration-enabling studies in gastric cancer,<br \/>\n      colorectal cancer and esophageal cancer. Registration-enabling trials of<br \/>\n      KEYTRUDA are also currently enrolling patients with melanoma, non-small<br \/>\n      cell lung cancer, head and neck cancer, bladder cancer, Hodgkin<br \/>\n      lymphoma, multiple myeloma, and breast cancer, and further trials are<br \/>\n      being planned for other malignancies.\n    <\/p>\n<p>\n      <b>Merck\u2019s Immuno-Oncology Data at the 2016 GI Cancers Symposium<\/b>\n    <\/p>\n<p>\n      A full listing of KEYTRUDA abstracts for both oral and poster sessions<br \/>\n      is below:\n    <\/p>\n<p>\n      <span class=\"bwuline\"><b>Oral Presentations<\/b><\/span>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #7) <\/b><\/i><b>Updated results for the advanced<br \/>\n        esophageal carcinoma cohort of the phase 1b KEYNOTE-028 study of<br \/>\n        pembrolizumab (MK-3475). <\/b>T. Doi.<b> <\/b>Poster Presentation:<br \/>\n        Thursday, Jan. 21, 12:30 \u2013 2:00 p.m. and 5:30 \u2013 7:00 p.m. PST. Oral<br \/>\n        Presentation: Thursday, Jan. 21, 2:00 \u2013 3:30 p.m. PST. Location:<br \/>\n        Moscone West Building.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #195) <\/b><\/i><b>PD-1 blockade in mismatch repair<br \/>\n        deficient non-colorectal gastrointestinal cancers. <\/b>D. Le. Poster<br \/>\n        Presentation: Friday, Jan. 22, 12:30 \u2013 2:00 p.m. and 5:30 \u2013 7:00 p.m.<br \/>\n        PST. Oral Presentation: Friday, Jan. 22, 2:00 \u2013 3:30 p.m. PST.<br \/>\n        Location: Moscone West Building.\n      <\/li>\n<\/ul>\n<p>\n      <span class=\"bwuline\"><b>Poster Presentations<\/b><\/span>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #TPS161) <\/b><\/i><b>Pembrolizumab (MK-3475) plus<br \/>\n        5-fluorouracil (5-FU) and cisplatin for first-line treatment of<br \/>\n        advanced gastric cancer: Preliminary safety data from KEYNOTE-059. <\/b>C.<br \/>\n        Fuchs.<b> <\/b>Thursday, Jan. 21, 12:30 \u2013 2:00 p.m. and 5:30 \u2013 7:00<br \/>\n        p.m. PST. Location: Moscone West Building.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #TPS183) <\/b><\/i><b>Pembrolizumab (MK-3475) versus<br \/>\n        paclitaxel as second-line therapy for advanced gastric or<br \/>\n        gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061<br \/>\n        study. <\/b>A. Ohtsu.<b> <\/b>Thursday, Jan. 21, 12:30 \u2013 2:00 p.m. and<br \/>\n        5:30 \u2013 7:00 p.m. PST. Location: Moscone West Building.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #TPS184) <\/b><\/i><b>Pembrolizumab (MK-3475) for<br \/>\n        recurrent or metastatic gastric or gastroesophageal junction (GEJ)<br \/>\n        adenocarcinoma: Multicohort phase II KEYNOTE-059 study. <\/b>C. Fuchs.<b><br \/>\n        <\/b>Thursday, Jan. 21, 12:30 \u2013 2:00 p.m. and 5:30 \u2013 7:00 p.m. PST.<br \/>\n        Location: Moscone West Building.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #TPS185) <\/b><\/i><b>KEYNOTE-062: Phase III study of<br \/>\n        pembrolizumab (MK-3475) alone or in combination with chemotherapy<br \/>\n        versus chemotherapy alone as first-line therapy for advanced gastric<br \/>\n        or gastroesophageal junction (GEJ) adenocarcinoma. <\/b>J. Tabernero.<b><br \/>\n        <\/b>Thursday, Jan. 21, 12:30 \u2013 2:00 p.m. and 5:30 \u2013 7:00 p.m. PST.<br \/>\n        Location: Moscone West Building.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #TPS189) <\/b><\/i><b>Pembrolizumab (MK-3475) for<br \/>\n        previously treated metastatic adenocarcinoma or squamous cell<br \/>\n        carcinoma of the esophagus: Phase II KEYNOTE-180 study. <\/b>M. Shah.<b><br \/>\n        <\/b>Thursday, Jan. 21, 12:30 \u2013 2:00 p.m. and 5:30 \u2013 7:00 p.m. PST.<br \/>\n        Location: Moscone West Building.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #465) <\/b><\/i><b>Phase 1\/2a study of double immune<br \/>\n        suppression blockade by combining a CSF1R inhibitor<br \/>\n        (pexidartinib\/PLX3397) with an anti PD-1 antibody (pembrolizumab) to<br \/>\n        treat advanced melanoma and other solid tumors. <\/b>Z. Wainberg.<b> <\/b>Friday,<br \/>\n        Jan. 22, 12:30 \u2013 2:00 p.m. and 5:30 \u2013 7:00 p.m. PST. Location: Moscone<br \/>\n        West Building.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #TPS787) <\/b><\/i><b>KEYNOTE-164: Phase II study of<br \/>\n        pembrolizumab (MK-3475) for patients with previously treated,<br \/>\n        microsatellite instability-high advanced colorectal carcinoma. <\/b>D.<br \/>\n        Le.<b> <\/b>Saturday, Jan. 23, 7:00 \u2013 7:55 a.m. and 12:30 \u2013 2:00 p.m.<br \/>\n        PST. Location: Moscone West Building.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #TPS789) <\/b><\/i><b>KEYNOTE-177: First-line,<br \/>\n        open-label, randomized, phase 3 study of pembrolizumab (MK-3475)<br \/>\n        versus investigator-choice chemotherapy for mismatch repair deficient<br \/>\n        or microsatellite instability-high metastatic colorectal carcinoma. <\/b>L<br \/>\n        Diaz.<b> <\/b>Saturday, Jan. 23, 7:00 \u2013 7:55 a.m. and 12:30 \u2013 2:00 p.m.<br \/>\n        PST. Location: Moscone West Building.\n      <\/li>\n<\/ul>\n<p>\n      <b>About Gastrointestinal Cancer<\/b>\n    <\/p>\n<p>\n      Gastrointestinal cancer is a term for a group of cancers that affect the<br \/>\n      digestive system, including cancers of the esophagus, gallbladder,<br \/>\n      liver, pancreas, stomach, small intestine, colon, rectum, and anus.<br \/>\n      Cancer of the colon or rectum, also called colorectal cancer, is the<br \/>\n      third most common cancer in men and the second most common cancer in<br \/>\n      women worldwide, accounting for more than 600,000 cases each year.<br \/>\n      Esophageal cancer, a type of cancer that begins in the inner layer of<br \/>\n      the esophagus, is the eighth most common cancer worldwide with an<br \/>\n      estimated 456,000 new cases diagnosed in 2012.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> (pembrolizumab) Injection<br \/>\n      100 mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States for the treatment of patients<br \/>\n      with unresectable or metastatic melanoma.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA. The NSCLC<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. An improvement in survival or<br \/>\n      disease-related symptoms has not yet been established. Continued<br \/>\n      approval for this indication may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      KEYTRUDA is administered at a dose of 2 mg\/kg as an intravenous infusion<br \/>\n      over 30 minutes every three weeks for the approved indications.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b><br \/>\n      (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis, including fatal cases, occurred in patients<br \/>\n      receiving KEYTRUDA. Pneumonitis occurred in 32 (2%) of 1,567 patients<br \/>\n      with melanoma, including Grade 1 (0.8%), 2 (0.8%), and 3 (0.4%)<br \/>\n      pneumonitis. Pneumonitis occurred in 19 (3.5%) of 550 patients with<br \/>\n      non-small cell lung cancer (NSCLC), including Grade 2 (1.1%), 3 (1.3%),<br \/>\n      4 (0.4%), or 5 (0.2%) pneumonitis. Monitor patients for signs and<br \/>\n      symptoms of pneumonitis. Evaluate suspected pneumonitis with<br \/>\n      radiographic imaging. Administer corticosteroids for Grade 2 or greater<br \/>\n      pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue<br \/>\n      KEYTRUDA for Grade 3 or 4 or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 31 (2%) of 1,567 patients with<br \/>\n      melanoma, including Grade 2 (0.5%), 3 (1.1%), and 4 (0.1%) colitis.<br \/>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients with NSCLC,<br \/>\n      including Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs<br \/>\n      and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in 16 (1%) of 1,567 patients with<br \/>\n      melanoma, including Grade 2 (0.1%), 3 (0.7%), and 4 (0.1%) hepatitis.<br \/>\n      Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 13 (0.8%) of 1,567 patients with melanoma,<br \/>\n      including Grade 2 (0.3%), 3 (0.3%), and 4 (0.1%) hypophysitis.<br \/>\n      Hypophysitis occurred in 1 (0.2%) of 550 patients with NSCLC, which was<br \/>\n      Grade 3 in severity. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 51 (3.3%) of 1,567 patients with melanoma,<br \/>\n      including Grade 2 (0.6%) and 3 (0.1%) hyperthyroidism. Hypothyroidism<br \/>\n      occurred in 127 (8.1%) of 1,567 patients with melanoma, including Grade<br \/>\n      3 (0.1%) hypothyroidism. Hyperthyroidism occurred in 10 (1.8%) of 550<br \/>\n      patients with NSCLC, including Grade 2 (0.7%) or 3 (0.3%)<br \/>\n      hyperthyroidism. Hypothyroidism occurred in 38 (6.9%) of 550 patients<br \/>\n      with NSCLC, including Grade 2 (5.5%) or 3 (0.2%) hypothyroidism. Thyroid<br \/>\n      disorders can occur at any time during treatment. Monitor patients for<br \/>\n      changes in thyroid function (at the start of treatment, periodically<br \/>\n      during treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA<br \/>\n      (pembrolizumab) for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2,117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in 7 (0.4%) of 1,567 patients with<br \/>\n      melanoma, including Grade 2 (0.2%), 3 (0.2%) and Grade 4 (0.1%)<br \/>\n      nephritis. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the immune-mediated adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 1567 patients<br \/>\n      with melanoma: arthritis (1.6%), exfoliative dermatitis, bullous<br \/>\n      pemphigoid, uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. The<br \/>\n      following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients with NSCLC: rash, vasculitis,<br \/>\n      hemolytic anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2,117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA (pembrolizumab).\n    <\/p>\n<p>\n      In Trial 6, KEYTRUDA was discontinued due to adverse reactions in 9% of<br \/>\n      555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions were fatigue (28% with<br \/>\n      KEYTRUDA vs. 28% with ipilimumab), diarrhea (26% with KEYTRUDA), rash<br \/>\n      (24% with KEYTRUDA vs. 23% with ipilimumab), and nausea (21% with<br \/>\n      KEYTRUDA). Corresponding incidence rates are listed for ipilimumab only<br \/>\n      for those adverse reactions that occurred at the same or lower rate than<br \/>\n      with KEYTRUDA.\n    <\/p>\n<p>\n      In Trial 2, KEYTRUDA was discontinued due to adverse reactions in 12% of<br \/>\n      357 patients with advanced melanoma; the most common (\u22651%) were general<br \/>\n      physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculo-papular rash (1%).<br \/>\n      The most common adverse reactions were fatigue (43% with KEYTRUDA),<br \/>\n      pruritus (28% with KEYTRUDA vs. 8% with chemotherapy), rash (24% with<br \/>\n      KEYTRUDA vs. 8% with chemotherapy), constipation (22% with KEYTRUDA vs.<br \/>\n      20% with chemotherapy), nausea (22% with KEYTRUDA), diarrhea (20% with<br \/>\n      KEYTRUDA vs. 20% with chemotherapy), and decreased appetite (20% with<br \/>\n      KEYTRUDA). Corresponding incidence rates are listed for chemotherapy<br \/>\n      only for those adverse reactions that occurred at the same or lower rate<br \/>\n      than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients with NSCLC. Serious adverse reactions occurred in 38% of<br \/>\n      patients. The most frequent serious adverse reactions reported in 2% or<br \/>\n      more of patients were pleural effusion, pneumonia, dyspnea, pulmonary<br \/>\n      embolism, and pneumonitis. The most common adverse reactions (reported<br \/>\n      in at least 20% of patients) were fatigue (44%), decreased appetite<br \/>\n      (25%), cough (29%), and dyspnea (23%).\n    <\/p>\n<p>\n      No formal pharmacokinetic drug interaction studies have been conducted<br \/>\n      with KEYTRUDA.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51261828&amp;newsitemid=20160119006164&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=89b7a0ab1810c2f9d8ebb2f50e89f436\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51261828&amp;newsitemid=20160119006164&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=d96721ea11499addfe5b0581333769a0\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51261828&amp;newsitemid=20160119006164&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=52013658883fc4e85cc64676e20bbf9f\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51261828&amp;newsitemid=20160119006164&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=e399b683f06de61168c5c6a532a1960e\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51261828&amp;newsitemid=20160119006164&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=05c4d8e6d9b6287572c896ed86427c07\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51261828&amp;newsitemid=20160119006164&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=07117793be4237a27d504a2b0f0328ba\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51261828&amp;newsitemid=20160119006164&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=7ac32ece3afdf0d5479f1a28f255d2be\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51261828&amp;newsitemid=20160119006164&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=fe6937931774af045537e90b604c0223\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and Patient Information\/Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51261828&amp;newsitemid=20160119006164&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=3b3fd20da61643325ab76a0510f1dfbc\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160119006164r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>An Phan,        908-255-6325<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Seven Registration-Enabling Trials Evaluating KEYTRUDA in Patients with Gastrointestinal Cancers are Planned or Underway Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new and updated findings investigating the use of KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in multiple gastrointestinal cancers will be presented at this year\u2019s Gastrointestinal (GI) Cancers Symposium in San Francisco, Jan. 21 \u2013 23. Updates on pembrolizumab include data on advanced esophageal carcinoma and new preliminary Phase 2 safety data in gastric cancer. \u201cAdvanced gastrointestinal cancers are difficult to treat and new therapies are needed,\u201d said Roger Dansey, M.D., senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. \u201cThrough our rapidly advancing clinical program, we have seen promising results with KEYTRUDA in several gastrointestinal cancers, and are hopeful about the potential of KEYTRUDA<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745423","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Data for KEYTRUDA\u00ae (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Data for KEYTRUDA\u00ae (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Seven Registration-Enabling Trials Evaluating KEYTRUDA in Patients with Gastrointestinal Cancers are Planned or Underway Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new and updated findings investigating the use of KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in multiple gastrointestinal cancers will be presented at this year\u2019s Gastrointestinal (GI) Cancers Symposium in San Francisco, Jan. 21 \u2013 23. Updates on pembrolizumab include data on advanced esophageal carcinoma and new preliminary Phase 2 safety data in gastric cancer. \u201cAdvanced gastrointestinal cancers are difficult to treat and new therapies are needed,\u201d said Roger Dansey, M.D., senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. \u201cThrough our rapidly advancing clinical program, we have seen promising results with KEYTRUDA in several gastrointestinal cancers, and are hopeful about the potential of KEYTRUDA\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\\\/\",\"name\":\"Data for KEYTRUDA\u00ae (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-01-19T10:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Data for KEYTRUDA\u00ae (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Data for KEYTRUDA\u00ae (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Data for KEYTRUDA\u00ae (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium - Merck.com","og_description":"Seven Registration-Enabling Trials Evaluating KEYTRUDA in Patients with Gastrointestinal Cancers are Planned or Underway Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new and updated findings investigating the use of KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in multiple gastrointestinal cancers will be presented at this year\u2019s Gastrointestinal (GI) Cancers Symposium in San Francisco, Jan. 21 \u2013 23. Updates on pembrolizumab include data on advanced esophageal carcinoma and new preliminary Phase 2 safety data in gastric cancer. \u201cAdvanced gastrointestinal cancers are difficult to treat and new therapies are needed,\u201d said Roger Dansey, M.D., senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. \u201cThrough our rapidly advancing clinical program, we have seen promising results with KEYTRUDA in several gastrointestinal cancers, and are hopeful about the potential of KEYTRUDA","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:02+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\/","name":"Data for KEYTRUDA\u00ae (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-01-19T10:00:00+00:00","dateModified":"2025-11-07T06:26:02+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-for-keytruda-pembrolizumab-in-a-range-of-gastrointestinal-cancers-to-be-presented-at-2016-gastrointestinal-cancers-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Data for KEYTRUDA\u00ae (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"3294004c-b590-43cd-a7f2-dd0db2c93b70","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Data-for-KEYTRUDA-pembrolizumab-in-a-Range-of-Gastrointestinal-Cancers-to-be-Presented-at-2016-Gastrointestinal-Cancers-Symposium-2016.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745423\/revisions"}],"predecessor-version":[{"id":3674812,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745423\/revisions\/3674812"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745423"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}